Related Experiment Video

Updated: May 23, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer

Haiyan Li1, Jun Lin, Xiaokai Wang

  • 1Department of Cell Biology, Southern Medical University, Guangzhou 510515, China.

Breast Cancer Research and Treatment
|April 6, 2012
PubMed

Insights

Targeting the mTORC2 pathway, not mTORC1, effectively inhibits breast cancer growth, migration, and promotes apoptosis. mTOR kinase inhibitors show promise for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Most breast cancers exhibit resistance to existing mammalian target of rapamycin complex 1 (mTORC1) inhibitors.
  • Emerging research highlights the mammalian target of rapamycin complex 2 (mTORC2) as a potential therapeutic target in cancer treatment.

Purpose of the Study:

  • To compare the efficacy of targeting mTORC1 versus mTORC2 in various breast cancer models.
  • To evaluate the therapeutic potential of mTOR kinase inhibitors in breast cancer treatment.

Main Methods:

  • Utilized breast cancer cell lines and xenograft models.
  • Administered mTOR kinase inhibitors (PP242, OSI-027), rapamycin, and employed gene knockdown (rictor, raptor).
  • Assessed cell proliferation, apoptosis, migration, and tumor growth in vivo.

Main Results:

  • mTOR kinase inhibitors (PP242, OSI-027) suppressed Akt phosphorylation and breast cancer cell proliferation.
  • Targeting mTORC2, but not mTORC1, promoted apoptosis and inhibited cell migration.
  • In vivo, PP242 effectively reduced tumor growth and induced apoptosis, unlike rapamycin.

Conclusions:

  • Inhibition of mTORC2 demonstrates superior efficacy over mTORC1 inhibition for breast cancer treatment.
  • mTOR kinase inhibitors represent a promising therapeutic strategy for breast cancers, warranting clinical investigation, potentially in combination with cisplatin.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...